CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Chinese regulator scrutinizes Apple’s AI rollout with Alibaba amid trade war; the Trump administration plans to extend restrictions to cover subsidiaries of sanctioned tech companies; and China announces scheme to convert confiscated cryptocurrency into cash
Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
SAMR adds new forms in which illegal acts of abusive administrative power to eliminate or restrict competition manifest, and clarifies the “appropriate confidentiality measures” in trade secrets protection. Permanent supplementation of working capital constitute a change in the purpose of offering proceeds
